uniQure N.V.
(NASDAQ:QURE) on Friday reported initial six-month follow-up data from the first low-dose cohort in its ongoing Phase 1/2a trial evaluating investigational gene therapy candidate AMT-260 in patients with refractory mesial temporal lobe epilepsy (MTLE).
MTLE represents the most prevalent and treatment-resistant subtype of drug-resistant epilepsy.
Read Also: FDA Signals uniQure Huntington Gene Therapy Data Could Back Accelerated Approval uniQure Reports Early Seizure Reductions In Initial AMT-260 Epilepsy Study The company said several patients experienced substantial reductions in disabling seizures, while the treatment continued to demonstrate a favorable safety profile.
According to data collected through May 29, 2026, three of the six patients receiving the low dose of AMT-260 achieved meaningful declines in disabling seizures during months four through six of follow-up.
